Ascendis Pharma AS ASND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $255.41
- Day Range
- $253.38–256.36
- 52-Week Range
- $176.34–282.00
- Bid/Ask
- $252.75 / $254.29
- Shares Outstanding
- 65.59M
- Market Cap
- $16.73B
- Volume/Avg
- 15,161 / 686,471
Key Statistics
- Price/Earnings (Normalized)
- 29.15
- Price/Sales
- 15.71
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.36%
Company Profile
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,189
- Website
- https://www.ascendispharma.com
Valuation
|
Metric
|
ASND
|
|---|---|
Price/Earnings (Normalized) | 29.15 |
Price/Book Value | 28.05 |
Price/Sales | 15.71 |
Price/Cash Flow | 127.32 |
Price/Earnings
ASND
Financial Strength
|
Metric
|
ASND
|
|---|---|
Quick Ratio | 0.68 |
Current Ratio | 1.00 |
Interest Coverage | −0.67 |
Quick Ratio
ASND
Profitability
|
Metric
|
ASND
|
|---|---|
Return on Assets (Normalized) | 44.52% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 80.80% |
Return on Assets
ASND
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Mx>CC%! | LOCK|H^VZ | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|K^bsl< | LOCK|P<kL@ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|QQGKrw | LOCK|%K& | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|k%X%W^! | LOCK|g?G#! | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<HT<qN | LOCK|kL | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Xt%f#& | LOCK|shxm | $29B | |||
| Incyte Corp
INCY
| LOCK|mk<<#c | LOCK|qQ& | $24B | |||
| Moderna Inc
MRNA
| LOCK|cP#Qwq | LOCK|GQ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|^&wMX! | LOCK|F^ | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<jt^Q% | LOCK|#V | $17B |
United States